menu
    • menu
    [{"orgOrder":0,"company":"Aveva Drug Delivery Sytems, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aveva Drug Delivery Sytems, Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Aveva Drug Delivery Sytems, Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aveva Drug Delivery Sytems, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Aveva Drug Delivery Sytems, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aveva Drug Delivery Sytems, Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Aveva Drug Delivery Sytems, Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aveva Drug Delivery Sytems, Inc \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Aveva Drug Delivery Sytems, Inc

    Menu

    Aveva Drug Delivery Sytems, Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aveva Drug Delivery Sytems, Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Aveva Drug Delivery Sytems, Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aveva Gets FDA Nod for First Generic Lidocaine 1.8% Patch

                            Details : FDA has granted approval for its generic Lidocaine 1.8% Patch, a non-opioid topical treatment for post-herpetic neuralgia (PHN), providing patients suffering from localized nerve pain.

                            Product Name : ZTlido-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 26, 2025

                            Lead Product(s) : Lidocaine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aveva Drug Delivery Sytems, Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Aveva Drug Delivery Sytems, Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aveva Launches Generic Fentanyl TDS, Third Complex Transdermal Drug in 15 Months

                            Details : Fentanyl TDS, a prescriptional 3-day transdermal patch is launched for managing moderate to severe chronic pain which is generic equivalent to Duragesic.

                            Product Name : Duragesic-Generic

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            February 17, 2025

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth